Oncobiologics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform. The Company has identified approximately eight biosimilar product candidates, of which two product candidates are ONS-3010 and ONS-1045. ONS-3010 is an adalimumab (Humira) biosimilar. The Company has initiated Phase III preparatory activities for ONS-3010. Its second product candidate, ONS-1045, is a bevacizumab (Avastin) biosimilar. The Company's other preclinical product candidate, ONS-1050, a trastuzumab (Herceptin) biosimilar, interferes with the human epidermal growth factor receptor 2 (HER2). ONS-4010 is a biosimilar to denosumab (Prolia/Xgeva), which is a human mAb. Its other biosimilar product, ONS-1055, is a biosimilar to cetuximab (Erbitux).
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:ONSIU
- CUSIP: N/A
- Web: oncobiologics.com/
- 50 Day Moving Avg: $5.09
- 200 Day Moving Avg: $5.09
- 52 Week Range: $4.56 - $5.50
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.02
- P/E Growth: 0.00
- Average Volume: 47,447 shs.
Frequently Asked Questions for Oncobiologics (NASDAQ:ONSIU)
What is Oncobiologics' stock symbol?
Oncobiologics trades on the NASDAQ under the ticker symbol "ONSIU."
Who are some of Oncobiologics' key competitors?
Some companies that are related to Oncobiologics include Incyte Corporation (INCY), Quintiles Transitional Holdings (Q), Alkermes PLC (ALKS), Alnylam Pharmaceuticals (ALNY), Qiagen N.V. (QGEN), Seattle Genetics (SGEN), Ionis Pharmaceuticals (IONS), United Therapeutics Corporation (UTHR), Icon Plc (ICLR), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), Exact Sciences Corporation (EXAS), PAREXEL International Corporation (PRXL), Bio-Techne Corp (TECH), ACADIA Pharmaceuticals (ACAD), WuXi PharmaTech (Cayman) (WX), Sage Therapeutics (SAGE) and Portola Pharmaceuticals (PTLA).
Who are Oncobiologics' key executives?
Oncobiologics' management team includes the folowing people:
- Pankaj Mohan Ph.D., Chairman of the Board, President, Chief Executive Officer
- Lawrence A. Kenyon, Chief Financial Officer, Secretary
- Scott Gangloff, Senior Vice President - Process Development and Manufacturing
- Stephen J. McAndrew Ph.D., Senior Vice President - Business Strategy & Development
- Kenneth M. Bahrt M.D., Chief Medical Officer
When did Oncobiologics IPO?
(ONSIU) raised $35 million in an IPO on Friday, May 13th 2016. The company issued 5,800,000 shares at $6.00 per share. Jefferies and Barclays served as the underwriters for the IPO and Cantor Fitzgerald & Co. was co-manager.
How do I buy Oncobiologics stock?
Shares of Oncobiologics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Oncobiologics' stock price today?
MarketBeat Community Rating for Oncobiologics (NASDAQ ONSIU)MarketBeat's community ratings are surveys of what our community members think about Oncobiologics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Oncobiologics stock can currently be purchased for approximately $4.62.
Consensus Ratings for Oncobiologics (NASDAQ:ONSIU) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating|
|Consensus Rating:||Hold (Score: 2.00)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Oncobiologics (NASDAQ:ONSIU)
(Data available from 8/17/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|3/7/2017||Jefferies Group LLC||Downgrade||Buy -> Hold||N/A|
|6/7/2016||Cantor Fitzgerald||Initiated Coverage||Buy||$15.00||N/A|
|6/7/2016||Barclays PLC||Initiated Coverage||Overweight||$11.00||N/A|
Earnings History for Oncobiologics (NASDAQ:ONSIU)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Oncobiologics (NASDAQ:ONSIU)
Current Year EPS Consensus Estimate: $-2.56 EPS
Next Year EPS Consensus Estimate: $-2.29 EPS
Dividend History for Oncobiologics (NASDAQ:ONSIU)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Oncobiologics (NASDAQ:ONSIU)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Oncobiologics (NASDAQ:ONSIU)
Latest Headlines for Oncobiologics (NASDAQ:ONSIU)
Oncobiologics (ONSIU) Chart for Thursday, August, 17, 2017